UW spinout DMD Therapeutics raises $400,000 from three foundations to advance DMD-813 toward human trials
DMD Therapeutics, a University of Washington spinout led by Ron Berenson, raised $400,000 from three DMD-focused foundations to advance its lead candidate DMD-813 — which showed positive results in mouse studies — toward human trials and early manufacturing.